Replies to post #101445 on Amarin Corp Plc (AMRN)

[staccani]

Thanks Sam.. the funny thing is that not only does Jeffries apply a 75% discount probability to top line but also consider in case of RIT success annual peak sale of $2.8B, ie less than 2 million annual patients... which is a tiny 4% global market penetration in the 0.5billion people with high Trigs globally, leaving the other 96% of the market untapped. I seriuosly doubt that, if RIT shows a 30%+ RRR improvement vs statin alone, 498M people and/or their doctors globally would do nothing serious (and I do not consider OTC products serious) to reduce their CVD risk